Overview

A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male Volunteers

Status:
Completed
Trial end date:
2021-06-22
Target enrollment:
Participant gender:
Summary
To compare the pharmacokinetics and safety between BR9004 and BR9004-1 in healthy male subjects after a single-dose administration while fasting.
Phase:
Phase 1
Details
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Treatments:
Abiraterone Acetate